PacingCure is all about innovation

PacingCure was founded in Amsterdam in 2016 as a spin-off company from the Amsterdam University Medical Center Heart Center and the Department of Medical Biology.

Led by world-class scientists and clinicians with a strong position within the cardiac community and patient groups, we are turning decades of knowledge into technologies for multiple cardiac diseases and clinical indications.

Gerard Boink, CEO, co-founder, is one of the leading experts on gene therapy for cardiac arrhythmias.

During his medicine study at the Amsterdam University Medical Center (AUMC), Dr. Gerard Boink, in collaboration with Dr. Hanno Tan, Prof. Jacques de Bakker and Prof. Vincent Christoffels, started research into genetic aspects of cardiac pacing, and continued this line of research at Columbia University (New, York, USA) with Prof. Michael Rosen. Dr. Boink holds an MSc in pharmaceutical sciences from Utrecht University (2006), an MSc in medicine from the University of Amsterdam (2006), and MD and PhD degrees from the University of Amsterdam (2013; both cum laude). His translational research has been supported by various prestigious personal and consortium grants, including grants from the Dutch Heart Foundation (Dr. Dekker Program), ZonMW (Veni), and European Research Council (Starting Grant and PoC Grants), and European Innovation Council (Pathfinder and Transition Grants).

Hanno Tan, CSO, co-founder, is Associate Professor of Cardiology and Principal Investigator of the Heart Center at the AUMC.

He started the biological pacemaker project at the AUMC in 2005 supported by a project grant of the Dutch Heart Foundation, and as a cardiologist has always had a keen eye for clinical applicability. Dr. Hanno Tan obtained several gene therapy-oriented grants from NWO (Take-Off), Health Holland (TKI), Dutch Heart Foundation, Rembrandt Institute for Cardiovascular Science, and Mkb-Innovatiestimulering regio en Topsectoren (MIT). He has also received various EU-funded grants (Horizon2020, EU-COST, FP7) and personal grants from ZonMW (Vici) and the Royal Netherlands Academy of Arts and Sciences (KNAW).

Osne Kirzner, CFO, joined PacingCure in 2016. He is an anesthesiologist and also holds a degree in finance and law.

Osne Kirzner handles PacingCure’s corporate and business development. Before joining PacingCure, he served the EQT Life Sciences (formerly LSP) team and, thereafter, served the AUMC’s board of directors researching the effects of strategic outsourcing contracts. He engaged in various specialized professional drug development programs and played an instrumental role in the application and execution of multiple Dutch and European financial SME instruments, such as Health Holland grants (2016 and 2019), NWO grants (2017, 2020), an Innovatiefonds Noord Holland loan (2019), Eureka grants (2020, 2021), and EIC grants (2022, 2023).

Klaus Neef, Head of Pre-Clinical Development, joined PacingCure in 2022.

He is a molecular biologist by training with a PhD degree in Biotechnology from the Institute of Genetics at the University of Cologne. After being involved in research projects on stem cells and regenerative therapies in Cologne and Singapore, Dr. Klaus Neef joined research groups in Utrecht and Amsterdam to focus on translating findings from basic research into clinically applicable therapies. At PacingCure, Dr. Klaus Neef is leading the development and coordination of pre-clinical studies and interactions with scientific and industry partners.